RT Journal Article
T1 Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain.
A1 Fuentes, Ana
A1 Serrano-Conde, Esther
A1 Roldán, Carolina
A1 Benito-Ruesca, Rafael
A1 Mejías, Gregoria
A1 Sampedro, Antonio
A1 March-Roselló, Gabriel
A1 Fernández-Natal, Isabel
A1 Esperalba, Juliana
A1 Rodríguez, Mario José
A1 Martínez de Aguirre, Paula
A1 Salas, Carlos
A1 Roc, María Lourdes
A1 Soria, Luis Miguel
A1 Parra-Grande, Mónica
A1 Montero, María Dolores
A1 Fernández-Roblas, Ricardo
A1 Franco-Álvarez de Luna, Francisco
A1 Lozano, Carmen
A1 García, Federico
K1 COVID-19
K1 Diagnosis
K1 IgA
K1 IgG
K1 IgM
K1 SARS-COV-2
AB To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used. Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively. The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
YR 2021
FD 2021-01-29
LK http://hdl.handle.net/10668/17065
UL http://hdl.handle.net/10668/17065
LA en
DS RISalud
RD Apr 5, 2025